Hyperactivated tumor survival pathways cannot be suppressed without coupling targeted inhibitors with companion diagnostics.
Because specific genomic alterations like PTEN deficiency drive rapid drug resistance and aggressive disease, regulatory approvals for next-generation inhibitors require mandatory matching companion diagnostics.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Gedatolisib's commercial success relies heavily on expanding routine biomarker companion diagnostics to identify the PIK3CA wild-type patients who benefit.
Clearance of next-generation kinase inhibitors is inextricably linked to the mandatory usage of companion diagnostic testing to prove pathway hyperactivation.
The regulatory clearance of Truqap is contingent upon the concurrent endorsement of a test to monitor target-specific PTEN loss.
Suppression of hyperactivated, PTEN-deficient tumor pathways requires a paired companion diagnostic tool to identify candidates at the point of treatment.